Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 9/2021

01-09-2021 | Seroma | Original Article

Intraoperative radiotherapy boost as part of breast-conservation therapy for breast cancer: a single-institution retrospective analysis

Authors: Raluca Stoian, Thalia Erbes, Constantinos Zamboglou, Jutta Scholber, Mark Gainey, Ilias Sachpazidis, Erik Haehl, Simon K. B. Spohn, Vivek Verma, David Krug, Alexander Rühle, Ingolf Juhasz-Böss, Anca-Ligia Grosu, Nils H. Nicolay, Tanja Sprave, MD, MBA

Published in: Strahlentherapie und Onkologie | Issue 9/2021

Login to get access

Abstract

Background

There are currently no data from randomized controlled trials on the use of intraoperative radiotherapy (IORT) as a tumor bed boost as part of a breast-conservation approach for breast cancer. This study retrospectively reviewed the safety and efficacy of IORT as a boost treatment at a tertiary cancer center.

Methods

From 2015 to 2019, patients underwent breast-conserving surgery with axillary lymph node staging and a single dose of 20 Gy IORT with 50-kV photons, followed by whole-breast irradiation (WBI) and adjuvant systemic therapy (if applicable). Patients were followed for assessment of acute and late toxicities (using the Common Terminology Criteria for Adverse Events version 5.0) at 3–6-month intervals. Outcomes included ipsilateral (IBTR) and contralateral breast progression-free survival (CBE), distant metastasis-free survival (DMFS), and overall survival (OS).

Results

Median follow-up for the 214 patients was 28 (range 2–59) months. Most patients had T1 disease (n = 124) and were clinically node negative. Only few patients had high-grade and/or triple-negative disease. The vast majority of patients underwent sentinel node biopsy, and 32 (15%) required re-resection for initially positive margins. Finally, all tumor bed margins were clear. Nine (4.2%) and 48 (22.4%) patients underwent neoadjuvant and adjuvant chemotherapy, respectively. WBI was predominantly performed as conventionally fractionated WBI (n = 187, 87.4%), and the median time from BCS to WBI was 54.5 days. IORT was delivered with a single dose of 20 Gy. The median WBI dose was 50 Gy (range 29.4–50.4 Gy). No patients experienced grade 4 events; acute grade 3 toxicities were limited to 17 (8%) cases of radiation dermatitis. Postoperative toxicities were mild. After WBI only one case of late grade ≥ 2 events was reported. There were two recurrences in the tumor bed and one contralateral breast event.

Conclusion

This investigation provides additional preliminary data supporting the using of IORT in the boost setting and corroborates the existing literature. These encouraging results should be prospectively validated by the eventual publication of randomized studies such as TARGIT‑B.
Literature
1.
Early Breast Cancer Trialists’ Collaborative G, Darby S, McGale P, Correa C, Taylor C, Arriagada R et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707–1716CrossRef
2.
Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J et al (2015) Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 16(1):47–56PubMedCrossRef
3.
4.
Pilar A, Gupta M, Ghosh Laskar S, Laskar S (2017) Intraoperative radiotherapy: review of techniques and results. ecancer 11:750CrossRef
5.
Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M et al (2014) Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5‑year results for local control and overall survival from the TARGIT‑A randomised trial. Lancet 383(9917):603–613PubMedCrossRef
6.
Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C et al (2013) Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 14(13):1269–1277PubMedCrossRef
7.
Fastner G, Reitsamer R, Urbanski B, Kopp P, Murawa D, Adamczyk B et al (2020) Toxicity and cosmetic outcome after hypofractionated whole breast irradiation and boost-IOERT in early stage breast cancer (HIOB): First results of a prospective multicenter trial (NCT01343459). Radiother Oncol 146:136–142PubMedCrossRef
8.
Valente SA, Tendulkar RD, Cherian S, Shah C, Ross DL, Lottich SC, Laronga C, Broman KK, Donnelly ED, Bethke KP, Shaw C, Lockney NA, Pederson A, Rudolph R, Hasselle M, Kelemen P, Hermanto U, Ashikari A, Kang S, Hoefer RA, McCready D, Fyles A, Escallon J, Rohatgi N, Graves J, Graves G, Willey SC, Tousimis E, Riley L, Deb N, Tu C, Small W Jr, Grobmyer SR (2021) TARGIT‑R (retrospective): 5‑year follow-up evaluation of intraoperative radiation therapy (IORT) for breast cancer performed in North America. Ann Surg Oncol 28(5):2512–2521. https://​doi.​org/​10.​1245/​s10434-020-09432-3. PMID: 33433786CrossRefPubMed
9.
Coombs NJ, Coombs JM, Vaidya UJ, Singer J, Bulsara M, Tobias JS et al (2016) Environmental and social benefits of the targeted intraoperative radiotherapy for breast cancer: data from UK TARGIT‑A trial centres and two UK NHS hospitals offering TARGIT IORT. BMJ Open 6(5):e10703PubMedPubMedCentralCrossRef
10.
Strnad V, Hannoun-Levi JM, Guinot JL, Lossl K, Kauer-Dorner D, Resch A, Recommendations from GEC ESTRO Breast Cancer Working Group (I) (2015) Target definition and target delineation for accelerated or boost Partial Breast Irradiation using multicatheter interstitial brachytherapy after breast conserving closed cavity surgery. Radiother Oncol 115(3):342–348PubMedCrossRef
11.
Wenz F, Welzel G, Blank E, Hermann B, Steil V, Sutterlin M et al (2010) Intraoperative radiotherapy as a boost during breast-conserving surgery using low-kilovoltage X‑rays: the first 5 years of experience with a novel approach. Int J Radiat Oncol Biol Phys 77(5):1309–1314PubMedCrossRef
12.
Pez M, Keller A, Welzel G, Abo-Madyan Y, Ehmann M, Tuschy B et al (2020) Long-term outcome after intraoperative radiotherapy as a boost in breast cancer. Strahlenther Onkol 196(4):349–355PubMedCrossRef
13.
Wenz F, Welzel G, Keller A, Blank E, Vorodi F, Herskind C et al (2008) Early initiation of external beam radiotherapy (EBRT) may increase the risk of long-term toxicity in patients undergoing intraoperative radiotherapy (IORT) as a boost for breast cancer. Breast 17(6):617–622PubMedCrossRef
14.
Kaiser J, Reitsamer R, Kopp P, Gaisberger C, Kopp M, Fischer T et al (2018) Intraoperative electron radiotherapy (IOERT) in the treatment of primary breast cancer. Breast Care 13(3):162–167PubMedPubMedCentralCrossRef
15.
Fastner G, Hauser-Kronberger C, Moder A, Reitsamer R, Zehentmayr F, Kopp P et al (2016) Survival and local control rates of triple-negative breast cancer patients treated with boost-IOERT during breast-conserving surgery. Strahlenther Onkol 192(1):1–7PubMedCrossRef
16.
Fastner G, Reitsamer R, Ziegler I, Zehentmayr F, Fussl C, Kopp P et al (2015) IOERT as anticipated tumor bed boost during breast-conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer—results of a case series after 5‑year follow-up. Int J Cancer 136(5):1193–1201PubMedCrossRef
17.
Belletti B, Vaidya JS, D’Andrea S, Entschladen F, Roncadin M, Lovat F et al (2008) Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding. Clin Cancer Res 14(5):1325–1332PubMedCrossRef
18.
Fabris L, Berton S, Citron F, D’Andrea S, Segatto I, Nicoloso MS et al (2016) Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway. Oncogene 35(37):4914–4926PubMedPubMedCentralCrossRef
19.
Clough KB, Kaufman GJ, Nos C, Buccimazza I, Sarfati IM (2010) Improving breast cancer surgery: a classification and quadrant per quadrant atlas for oncoplastic surgery. Ann Surg Oncol 17(5):1375–1391PubMedCrossRef
20.
Yang Z, Chen J, Hu W, Pan Z, Cai G, Yu X et al (2010) Planning the breast boost: how accurately do surgical clips represent the CT seroma? Radiother Oncol 97(3):530–534PubMedCrossRef
21.
Goldberg H, Prosnitz RG, Olson JA, Marks LB (2005) Definition of postlumpectomy tumor bed for radiotherapy boost field planning: CT versus surgical clips. Int J Radiat Oncol Biol Phys 63(1):209–213PubMedCrossRef
22.
Steel GG, Deacon JM, Duchesne GM, Horwich A, Kelland LR, Peacock JH (1987) The dose-rate effect in human tumour cells. Radiother Oncol 9(4):299–310PubMedCrossRef
23.
Whelan TJ, Kim DH, Sussman J (2008) Clinical experience using hypofractionated radiation schedules in breast cancer. Semin Radiat Oncol 18(4):257–264PubMedCrossRef
24.
Williams MV, Denekamp J, Fowler JF (1985) A review of alpha/beta ratios for experimental tumors: implications for clinical studies of altered fractionation. Int J Radiat Oncol Biol Phys 11(1):87–96PubMedCrossRef
25.
Group ST, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ et al (2008) The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 371(9618):1098–1107CrossRef
26.
Group ST, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ et al (2008) The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 9(4):331–341CrossRef
27.
Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ et al (2013) The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14(11):1086–1094PubMedCrossRef
28.
Owen JR, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J et al (2006) Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol 7(6):467–471PubMedCrossRef
29.
Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L et al (2002) Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 94(15):1143–1150PubMedCrossRef
30.
Hopwood P, Haviland JS, Sumo G, Mills J, Bliss JM, Yarnold JR et al (2010) Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‑year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncol 11(3):231–240PubMedCrossRef
31.
Brunt AM, Haviland JS, Sydenham M, Agrawal RK, Algurafi H, Alhasso A et al (2020) Ten-year results of FAST: a randomized controlled trial of 5‑fraction whole-breast radiotherapy for early breast cancer. J Clin Oncol 38(28):3261–3272PubMedCrossRefPubMedCentral
32.
Gupta A, Khan AJ, Yegya-Raman N, Sayan M, Ahlawat S, Ohri N et al (2019) 5‑year results of a prospective phase 2 trial evaluating 3‑week hypofractionated whole breast radiation therapy inclusive of a sequential boost. Int J Radiat Oncol Biol Phys 105(2):267–274PubMedCrossRef
33.
Choi KH, Ahn SJ, Jeong JU, Yu M, Kim JH, Jeong BK et al (2020) Postoperative radiotherapy with intensity-modulated radiation therapy versus 3‑dimensional conformal radiotherapy in early breast cancer: a randomized clinical trial of KROG 15-03. Radiother Oncol 154:179–186PubMedCrossRef
34.
Krug D, Koder C, Hafner MF, Arians N, Harrabi SB, Koerber SA et al (2020) Acute toxicity of normofractionated intensity modulated radiotherapy with simultaneous integrated boost compared to three-dimensional conformal radiotherapy with sequential boost in the adjuvant treatment of breast cancer. Radiat Oncol 15(1):235PubMedPubMedCentralCrossRef
35.
Joseph K, Vos LJ, Gabos Z, Pervez N, Chafe S, Tankel K, Warkentin H, Ghosh S, Amanie J, Powell K, Polkosnik LA, Horsman S, MacKenzie M, Sabri S, Parliament MB, Mackey J, Abdulkarim B (2021) Skin toxicity in early breast cancer patients treated with field-in-field breast intensity-modulated radiotherapy versus helical inverse breast intensity-modulated radiotherapy: results of a phase III Randomised controlled trial. Clin Oncol (R Coll Radiol) 33(1):30–39. https://​doi.​org/​10.​1016/​j.​clon.​2020.​07.​005. PMID: 32711920CrossRef
36.
Blank E, Kraus-Tiefenbacher U, Welzel G, Keller A, Bohrer M, Sutterlin M et al (2010) Single-center long-term follow-up after intraoperative radiotherapy as a boost during breast-conserving surgery using low-kilovoltage x‑rays. Ann Surg Oncol 17(Suppl 3):352–358PubMedCrossRef
37.
Chang DW, te Marvelde L, Chua BH (2014) Prospective study of local control and late radiation toxicity after intraoperative radiation therapy boost for early breast cancer. Int J Radiat Oncol Biol Phys 88(1):73–79PubMedCrossRef
38.
Fastner G, Sedlmayer F, Merz F, Deutschmann H, Reitsamer R, Menzel C et al (2013) IORT with electrons as boost strategy during breast conserving therapy in limited stage breast cancer: long term results of an ISIORT pooled analysis. Radiother Oncol 108(2):279–286PubMedCrossRef
39.
Ivaldi GB, Leonardi MC, Orecchia R, Zerini D, Morra A, Galimberti V et al (2008) Preliminary results of electron intraoperative therapy boost and hypofractionated external beam radiotherapy after breast-conserving surgery in premenopausal women. Int J Radiat Oncol Biol Phys 72(2):485–493PubMedCrossRef
40.
Lemanski C, Azria D, Thezenas S, Gutowski M, Saint-Aubert B, Rouanet P et al (2006) Intraoperative radiotherapy given as a boost for early breast cancer: long-term clinical and cosmetic results. Int J Radiat Oncol Biol Phys 64(5):1410–1415PubMedCrossRef
41.
Sedlmayer F, Reitsamer R, Fussl C, Ziegler I, Zehentmayr F, Deutschmann H et al (2014) Boost IORT in breast cancer: body of evidence. Int J Breast Cancer 2014:472516PubMedPubMedCentralCrossRef
42.
Vaidya JS, Baum M, Tobias JS, Wenz F, Massarut S, Keshtgar M et al (2011) Long-term results of targeted intraoperative radiotherapy (Targit) boost during breast-conserving surgery. Int J Radiat Oncol Biol Phys 81(4):1091–1097PubMedCrossRef
43.
Wong WW, Pockaj BA, Vora SA, Halyard MY, Gray RJ, Schild SE (2014) Six-year outcome of a prospective study evaluating tumor bed boost with intra-operative electron irradiation followed by whole-breast irradiation for early-stage breast cancer. Breast J 20(2):125–130PubMedCrossRef
Metadata
Title
Intraoperative radiotherapy boost as part of breast-conservation therapy for breast cancer: a single-institution retrospective analysis
Authors
Raluca Stoian
Thalia Erbes
Constantinos Zamboglou
Jutta Scholber
Mark Gainey
Ilias Sachpazidis
Erik Haehl
Simon K. B. Spohn
Vivek Verma
David Krug
Alexander Rühle
Ingolf Juhasz-Böss
Anca-Ligia Grosu
Nils H. Nicolay
Tanja Sprave, MD, MBA
Publication date
01-09-2021
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 9/2021
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-021-01785-2

Other articles of this Issue 9/2021

Strahlentherapie und Onkologie 9/2021 Go to the issue

Literatur kommentiert

Moderate Hypofraktionierung beim Harnblasenkarzinom – ein neuer Versorgungsstandard?

Literatur kommentiert

Konditionierung mit Ganzkörperbestrahlung oder Chemotherapie bei ALL im Kindesalter

Original Article

Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial

Original Article

MicroRNA-29b regulates the radiosensitivity of esophageal squamous cell carcinoma by regulating the BTG2-mediated cell cycle

Case Study

Inoperable CASTLE of the thyroid gland treated with radical radiotherapy with complete remission

Review Article

Value of PET imaging for radiation therapy